METHODS AND RESULTS: This prospective, multicentre, non-randomised study enrolled 25
STEMI patients undergoing PPCI; a
nitinol, self-expanding, coronary
stent (STENTYS®
stent; STENTYS, Paris, France) was used in all patients. Angiography and intravascular ultrasound (IVUS) or optical coherence tomography (OCT) were performed immediately after
stent deployment, after three days and at six months. Primary safety endpoints were mortality, reinfarction,
stent thrombosis and
stroke at discharge and at six months. The primary feasibility endpoints were technical, device and procedural success, and
stent apposition at three days and six months. Secondary endpoints included distal embolisation, binary restenosis, ischaemia-driven target lesion revascularisation (TLR) and late lumen loss (LLL). There were no adverse events at discharge or at six months. Technical, device and procedural success were 100%, 96% and 96%, respectively. IVUS showed a significant vasodilatation distal to the culprit lesion at three-day follow-up (+19%), with a concordant expansion of the implanted
stent (+18%), p≤0.001 for both values. One case of distal embolisation was reported. There were no cases of late
stent malapposition at six months. In-
stent and in-segment LLL were 0.71±0.71 mm and 0.58±0.61 mm. Binary restenosis was 25%, ischaemia-driven TLR was 12%.
CONCLUSIONS: This study shows that the use of the STENTYS® self-expanding
stent is safe and feasible in
STEMI patients. Three days after the procedure, the
stent expanded to the same extent as the epicardial vasodilatation and appeared completely apposed to the vessel wall. This could be of benefit in preventing
stent thrombosis in the setting of
STEMI.